Alerts will be sent to your verified email
Verify EmailPANACEABIO
Panacea Biotec
|
Indoco Remedies
|
Novartis
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
6.0 . | 54.0 . | n/a |
R&D as a % of Total Sales
|
9.86 % | 5.7 % | n/a |
Financials
|
|||
5 yr Average ROE
|
17.16 % | 8.94 % | 8.0 % |
5yr average Equity Multiplier
|
1.61 | 1.9 | 2.72 |
5yr Average Asset Turnover Ratio
|
0.4 | 0.88 | 0.18 |
5yr Avg Net Profit Margin
|
19.26 % | 5.41 % | 17.12 % |
Price to Book
|
3.13 | 2.72 | 2.85 |
P/E
|
227.93 | 0.0 | 21.77 |
5yr Avg Cash Conversion Cycle
|
-102.87 Days | 35.3 Days | -23.33 Days |
Inventory Days
|
109.97 Days | 70.6 Days | 44.27 Days |
Days Receivable
|
37.7 Days | 83.16 Days | 38.18 Days |
Days Payable
|
294.14 Days | 111.01 Days | 124.28 Days |
5yr Average Interest Coverage Ratio
|
2.9 | 7.53 | 65.43 |
5yr Avg ROCE
|
-1.68 % | 13.6 % | 5.91 % |
5yr Avg Operating Profit Margin
|
-1.99 % | 14.97 % | 15.15 % |
5 yr average Debt to Equity
|
0.05 | 0.49 | 0.0 |
5yr CAGR Net Profit
|
-64.03 % | n/a | 37.01 % |
5yr Average Return on Assets
|
6.95 % | 5.31 % | 3.13 % |
Shareholdings
|
|||
Promoter Holding
|
72.48 % | 58.9 % | 70.68 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-1.11 % | 0.21 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 1.16 % | 0.0 |
Panacea Biotec
|
Indoco Remedies
|
Novartis
|
|
---|---|---|---|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
Capex
|
Capex
|
-
|
-
|
Brand Wise Break-Up
|
Brand Wise Break-Up
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|